Search
Zonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigationalThe US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383] … [L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors
Neomycin
go.drugbank.com/drugs/DB00994ApprovedInvestigationalVet approved[A175042] Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is … also used in combination with [polymyxin B] sulfates and [hydrocortisone] in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by
Mixtures: Bus and Classroom Yellow, Care Bus and Classroom YellowDipivefrin
go.drugbank.com/drugs/DB00449ApprovedWithdrawnDipivefrin is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops).
Yellow fever vaccine
go.drugbank.com/drugs/DB10805ApprovedInvestigationalYellow fever vaccine prevents against Yellow Fever, a viral hemorrhagic disease caused by the transmission of a _flavivirus_ through the bite of an infected mosquito. … Yellow Fever Vaccine is a subcutaneously administered vaccination for the active immunization and prophylaxis of yellow fever in pediatric patients 9 months of age and older.
Belzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigational[L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. … by Merck in 2019).
Metolazone
go.drugbank.com/drugs/DB00524ApprovedInvestigationalA quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.
Beremagene geperpavec
go.drugbank.com/drugs/DB17831ApprovedInvestigational[A259771] Beremagene geperpavec is genetically modified to deliver _COL7A1_, thereby restoring the levels of the COL7 protein.[L46551] … Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).
Olezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigational[A264888,A264893] Olezarsen is conjugated to a ligand containing three N-acetyl-galactosamine (GalNAc) residues to enable its delivery to hepatocytes. … [A264888] Olezarsen works to reduce the plasma triglyceride levels by reducing APOC3 production.
Nirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.
Voxelotor
go.drugbank.com/drugs/DB14975Approved[L10403] It was developed by Global Blood Therapeutics, Inc.